We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00663182
Recruitment Status : Unknown
Verified April 2008 by Shanghai Changzheng Hospital.
Recruitment status was:  Enrolling by invitation
First Posted : April 22, 2008
Last Update Posted : April 23, 2008
Information provided by:
Shanghai Changzheng Hospital

April 21, 2008
April 22, 2008
April 23, 2008
January 2008
December 2010   (Final data collection date for primary outcome measure)
  • liver function [ Time Frame: 1 year ]
  • HBV-DNA [ Time Frame: 1 year ]
liver function and HBV-DNA [ Time Frame: 1 year ]
Complete list of historical versions of study NCT00663182 on ClinicalTrials.gov Archive Site
  • disease progression [ Time Frame: 2 years ]
  • hepatocellular carcinoma [ Time Frame: 2 year ]
  • Child-Pugh score [ Time Frame: 2 year ]
  • motality [ Time Frame: 2 year ]
disease progression,hepatocellular carcinoma,Child-Pugh score [ Time Frame: 2 years ]
Not Provided
Not Provided
Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis
Entecavir for Patients With Decompensated HBV-Related Cirrhosis:a Prospective Randomized Controlled Trial
The aim of this study is to evaluate the effect of Entecavir for patients With decompensated HBV-Related cirrhosis.

Chronic hepatitis B is one of the most widespread viral infections worldwide, potentially leading to liver cirrhosis and hepatocellular carcinoma. Previous studies demonstrated that patients with active viral replication, defined as the presence of detectable serum HBV-DNA or HBeAg, were at increased risk of developing progressive liver disease or death.The prognosis of decompensated cirrhosis resulting from chronic hepatitis B virus infection is poor. Anti-viral therapy in decompensated HBV-related cirrhosis has been recommended by the American Association for the Study of Liver Diseases. However, no high quality research on the effectiveness of anti-viral therapy in decompensated cirrhosis has been performed.

Entecavir is a new nucleotide analogue, which has been proved effective in suppressing viral replication and decreasing the necroinflammatory response, was recommended as a first-line medication in AASLD guideline. Our purpose was to evaluate the effect of Entecavir for patients With decompensated HBV-Related cirrhosis. The main outcomes were liver function, HBV-DNA, disease progression, hepatocellular carcinoma, Child-Pugh score and the survival.

Phase 4
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Hepatitis B Virus
  • Decompensated Cirrhosis
Drug: Entecavir
Entecavir 0.5 mg/d
Other Name: Baraclude
  • Experimental: A
    Patients with decompensated HBV-related cirrhosis
    Intervention: Drug: Entecavir
  • No Intervention: B

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Unknown status
December 2012
December 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. over 16 years of age;
  2. evidence of active viral replication was documented by a positive test for HBV-DNA in serum;
  3. Liver cirrhosis was proven by ultrasound or CT;
  4. Decompensated cirrhosis was evidenced by a Child-Pugh score ≥ 7;
  5. patients had decompensation signs such as jaundice, ascites, variceal bleeding, hepatic encephalopathy

Exclusion Criteria:

  1. evidence of hepatocellular carcinoma (suspicious foci on hepatic ultrasonography at screening or a rising serum level of alpha-fetoprotein)
  2. a serum alanine aminotransferase level more than 10 times the upper limit of normal
  3. coinfection with hepatitis C or D virus or human immunodeficiency virus
  4. other types of cirrhosis
  5. a history of anti-viral therapy
  6. a total bilirubin level higher than 170 mmol/L
  7. a history of malignant tumors
Sexes Eligible for Study: All
16 Years and older   (Child, Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Jian Shi, Shanghai Changzheng Hospital
Shanghai Changzheng Hospital
Not Provided
Principal Investigator: Jian Shi, MD Shanghai Changzheng Hospital
Shanghai Changzheng Hospital
April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP